A new drug against aggressive lung cancer reduced the risk of death by 54%
A new drug against aggressive lung cancer reduced the risk of death by 54% Українські Національні Новини (УНН)
Онкология
Рак лёгких
393 материалов по теме, собраны автоматически из проверенных источников
🎗️
Онкология
Enhertu Delays Progression in HER2-Mutant Lung Cancer in Phase 3 Trial
Enhertu Delays Progression in HER2-Mutant Lung Cancer in Phase 3 Trial Cure Today
Онкология
AI tool successfully predicts outcomes of immunotherapy in lung cancer
Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine. The study reported findings from the I3LUNG project, a large international trial…
Онкология
Rybrevant’s Second Act: How J&J Is Rewriting the Rules for EGFR-Mutant Lung Cancer
Rybrevant’s Second Act: How J&J Is Rewriting the Rules for EGFR-Mutant Lung Cancer The Clinical Trial Vanguard
Онкология
Gotistobart Nearly Doubled Median Survival Versus Chemotherapy in 87 Patient Lung Cancer Trial Stage, Pivotal Data Pending
Gotistobart Nearly Doubled Median Survival Versus Chemotherapy in 87 Patient Lung Cancer Trial Stage, Pivotal Data Pending Medical Daily
Онкология
GSK showcases positive data with lung cancer drugs at WCLC
GSK showcases positive data with lung cancer drugs at WCLC pharmaphorum
🎗️
Онкология
BioNTech stock jumps on positive lung cancer trial data
BioNTech stock jumps on positive lung cancer trial data Investing.com
Онкология
AI Tool Successfully Predicts Outcomes of Immunotherapy in Lung Cancer | Newswise
AI Tool Successfully Predicts Outcomes of Immunotherapy in Lung Cancer | Newswise newswise.com
Онкология
FDA Approves Bayer’s Sevabertinib as First-Line Treatment for Adults Living with HER2-Mutant Lung Cancer
FDA Approves Bayer’s Sevabertinib as First-Line Treatment for Adults Living with HER2-Mutant Lung Cancer geneonline.com
🎗️
Онкология
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech says lung cancer drug candidate prolonged lives in trial The Mighty 790 KFGO
🎗️
Онкология
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech says lung cancer drug candidate prolonged lives in trial WTVB
🎗️
Онкология
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech says lung cancer drug candidate prolonged lives in trial Reuters
Онкология
Amivantamab plus chemotherapy achieves 34.3-month OS in EGFR exon 20 insertion lung cancer
Amivantamab plus chemotherapy achieves 34.3-month OS in EGFR exon 20 insertion lung cancer The Clinical Trial Vanguard
Онкология
Tam-Peli Extends Survival to 13.3 Months in Relapsed Small-Cell Lung Cancer
Tam-Peli Extends Survival to 13.3 Months in Relapsed Small-Cell Lung Cancer The Clinical Trial Vanguard
Онкология
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial miragenews.com